Mobilization and Collection of Autologous HSCS in Patients With Mm in Daratumumab Era. Experience of a Single Center.

Key Points

• Effective mobilization and collection of autologous HSCs enhances treatment for multiple myeloma.
• The collection success rate and overall yield were significantly improved with the use of daratumumab.
• Observational analysis at a single center provides crucial insights into clinical practices.
• Further investigation is needed to establish long-term outcomes in multiple myeloma patients.